Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2) Meeting Abstract

  

Authors:	Hurwitz, H.; Van Cutsem, E.; Bendell, J. C.; Hidalgo, M.; Li, C. P.; Garrido, M.; Macarulla, T. M.; Sahai, V.; Sama, A. R.; Greeno, E.; Yu, K. H.; Verslype, C.; Dawkins, F. W.; Walker, C.; Clark, J.; O'Reilly, E. M.
Abstract Title:	Two randomized, placebo-controlled phase 3 studies of ruxolitinib (Rux) + capecitabine (C) in patients (pts) with advanced/metastatic pancreatic cancer (mPC) after failure/intolerance of first-line chemotherapy: JANUS 1 (J1) and JANUS 2 (J2)
Meeting Title:	2017 Gastrointestinal Cancers Symposium
Journal Title:	Journal of Clinical Oncology
Volume:	35
Issue:	4 Suppl.
Meeting Dates:	2017 Jan 19-21
Meeting Location:	San Francisco, CA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2017-02-01
Language:	English
ACCESSION:	WOS:000443281700334
PROVIDER:	wos
DOI:	10.1200/JCO.2017.35.4_suppl.343
Notes:	Meeting Abstract: 343 -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/147165